EgnsINVEST Ejendomme Tyskland Q3 2026 EBVAT seen at DKK 4.1 million; revenue seen at DKK 15.6 million
Bitget2026/10/08 10:06EgnsINVEST Ejendomme Tyskland expects Q3 2026 revenue of DKK 15.6 million and EBVAT of DKK 4.1 million, in line with budget. Guidance for the year stays unchanged, with EBVAT projected at DKK 15 million to DKK 17 million. Property values are expected to post a positive adjustment of DKK 6.3 million in Q3 2026, while yield requirements are described as unchanged. Apartment renovations on tenant move-outs are cited as supporting higher rents, alongside efforts to raise rents on re-letting commercial space. Share buyback program repurchased 15,386 shares for DKK 2,240,128 through Sept. 30, aimed at reducing share capital. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EgnsINVEST Ejendomme Tyskland A/S published the original content used to generate this news brief on October 08, 2026, and is solely responsible for the information contained therein.
- EgnsINVEST Ejendomme Tyskland expects Q3 2026 revenue of DKK 15.6 million and EBVAT of DKK 4.1 million, in line with budget.
- Guidance for the year stays unchanged, with EBVAT projected at DKK 15 million to DKK 17 million.
- Property values are expected to post a positive adjustment of DKK 6.3 million in Q3 2026, while yield requirements are described as unchanged.
- Apartment renovations on tenant move-outs are cited as supporting higher rents, alongside efforts to raise rents on re-letting commercial space.
- Share buyback program repurchased 15,386 shares for DKK 2,240,128 through Sept. 30, aimed at reducing share capital.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
